AsianScientist (Oct. 19, 2016) – Biopharmaceutical company Crescendo Biologics and Takeda Pharmaceutical has announced a collaboration and license agreement for the discovery, development and commercialization of Humabody®-based therapeutics for cancers with a high unmet medical need.
Located in Cambridge, UK, Crescendo Biologics is involved in discovering and developing potent, highly differentiated Humabody® therapeutics with a focus on cancer. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas, and vaccines as well.
Humabodies® are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human VH domain building blocks. Humabodies® have biophysical properties enabling the extremely rapid and efficient assembly and screening of a variety of bi- and multi-specific Humabody® candidates, opening new routes to novel biology and modes-of-action.
Under the terms of the agreement, Crescendo is eligible to receive up to US$36 million, in a combination of an upfront payment, investment, research funding and preclinical milestones. Takeda will have the right to develop and commercialize Humabody®-based therapeutics resulting from the collaboration. Crescendo is also eligible to receive further clinical development, regulatory and sales-based milestone payments of up to US$754 million.
In addition, Crescendo will be eligible to receive royalties on Humabody®-based product sales by Takeda.
Source: Takeda; Photo: Takeda, Crescendo Biologics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.